Kite Pharma Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Kite Pharma stocks.

Kite Pharma

Kite Pharma, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors (CAR-T).
The Santa Monica, California-based company was founded in 2009 by Arie Belldegrun, M.D., FACS, an Israeli-American oncologist, who served as the company's chairman, president and chief executive officer.On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, equating to $180 cash per share. The deal will add the promising CAR-T candidate to Gilead's existing portfolio. The acquisition was completed in October 2017. In October 2017, Kite Pharma’s therapy, Yescarta (axicabtagene ciloleucel) became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.MIT Technology Review ranked Kite Pharma 7th in its annual list of 50 Smartest Companies 2017.

Browse All Tags